Stockwatch: Don't Fear The Pricing Reaper
The drug pricing debate has tarred many brushes in the pharmaceutical value chain. Whilst politicians may not yet be able to distinguish between the brazen price inflation of generic drugs and the high prices of innovative and recently launched branded drugs, the debate and rhetoric will eventually polarize. That polarization may be helped by new drugs with potentially very high list prices that are destined to be prescribed to very few patients.
You may also be interested in...
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.
When AstraZeneca closed out big pharma earnings season, its usually dominant therapeutic franchise missed analysts’ expectations. Merck’s, on the other hand, did not disappoint.
The sales performances of the GLP-1 agonists dominated the earnings of Novo Nordisk and Lilly, with both stocks hitting 52-week highs after their results. But one moved ahead of the other in an important strategic bottleneck.